A new oral sustained release formulation containing 20 mg nifedipine (Coral retard) was administered twice daily to 30 patients suffering from coronary diseases and/or hypertension, in order to assess its clinical effectiveness. The controls of blood pressure and pain before, during and after 30 days of treatment revealed a significantly good therapeutic action of the new formulation, both as an antihypertensive and an antianginal remedy. Blood examinations exhibited an optimum tolerability of the test product. Moreover, in 8 additional subjects free of cardiovascular and other diseases, the formulation was compared to a commercial sustained release product in order to evaluate its bioavailability after a single 20 mg dose. The product under study showed a satisfactory bioavailability when compared to the reference product. It is concluded that the new formulation can be successfully applied to the treatment of hypertensive and/or coronary diseases with a considerable simplification of the dosing schedule and an improved patient compliance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prokinetic agents are drugs used to enhance gastrointestinal motility and treat disorders such as Gastroesophageal Reflux Disease (GERD) and gastroparesis. pH-dependent release systems offer targeted drug delivery, allowing prokinetic agents to be released specifically in desired regions of the gastrointestinal tract. This optimizes drug efficacy and minimizes systemic side effects.
View Article and Find Full Text PDFDeterioration of preexisting myoclonus following nifedipine use in parkinsonian syndrome: A case report.
eNeurologicalSci
March 2025
Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
L-type calcium channel antagonists are uncommon causes of myoclonus, and the underlying mechanism remains unclear. Here, we report a case of parkinsonian syndrome with deterioration of preexisting myoclonus after nifedipine use. A 96-year-old woman was administered a single dose of sustained-release nifedipine for chest pain.
View Article and Find Full Text PDFAchieving enhanced stabilization and controlled release of curcumin cross-linked polydopamine particles.
Heliyon
January 2025
Department of Polymer Engineering and Color Technology, Amirkabir University of Technology, P.O. Box 15875-4413, Tehran, Iran.
Development of efficient drug delivery systems remains a critical challenge in pharmaceutical applications, necessitating novel approaches to improve drug loading and release profiles. In this study, a novel method is presented for fabricating crosslinked polydopamine particles (XPDPs) using a water/water Pickering emulsion system. The emulsion is composed of poly(ethylene glycol) and dextran, stabilized by polydopamine (PDA) particles.
View Article and Find Full Text PDFInsights into bacterial cellulose for adsorption and sustained-release mechanism of flavors.
Food Chem X
January 2025
Flavors and Fragrance Engineering & Technology Research Center of Henan Province, College of Tobacco Science, Henan Agricultural University, Zhengzhou 450002, China.
The stabilities and sustained-release properties of citral are significant for foods. Herein, bacterial cellulose (BC) was innovatively reported for adsorption and sustained-release of citral via gas-phase adsorption technique, and the adsorption mechanism was disclosed. BC was prepared from tobacco stem waste extract (TSWE), and better adsorption capacity (124.
View Article and Find Full Text PDFISG15-LFA1 interactions in latent HIV clearance: mechanistic implications in designing antiviral therapies.
Front Cell Dev Biol
December 2024
Biomedical Research Institute of Southern California, Oceanside, CA, United States.
Interferon types-I/II (IFN-αβ/γ) secretions are well-established antiviral host defenses. The human immunodeficiency virus (HIV) particles are known to prevail following targeted cellular interferon secretion. CD4 T-lymphocytes are the primary receptor targets for HIV entry, but the virus has been observed to hide (be latent) successfully in these cells through an alternate entry route via interactions with LFA1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!